BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

31 March 2021

“Banche e industria, un binomio vincente nella crisi pandemica”– Tavola rotonda online, ospite il presidente di FIT Giorgio Calderari

25 March 2021

Corriere del Ticino “La crisi si può superare solo con il gioco di squadra” Tavola rotonda Abt, ospite il presidente di FIT, Giorgio Calderari

25 March 2021

La Regione “Covid, un’economia comunque resiliente” Tavola rotonda Abt, ospite il presidente di Farma Industria Ticino, Giorgio Calderari

25 March 2021

3B FUTURE HEALTH GP S.A.R.L. ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II

24 March 2021

Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms (Nausea and Vomiting) Associated with Cancer Chemotherapy

23 March 2021

Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock

22 March 2021

Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting

18 March 2021

Teleticino – “Facevamo tamponi di massa già da tempo” Intervista a Giorgio Calderari, presidente FIT e Group General Manager di Helsinn

16 March 2021

Creare alleanze produttive per i vaccini – L’opinione del Presidente FIT Giorgio Calderari

26 February 2021